Published online in Nature Biotechnology, the landmark study is the first to document the potential clinical utility of regenerating damaged heart muscle by injecting hESC-derived cardiomyocytes directly into the site of the infarct. In addition, the research confirms the effectiveness of a scalable production system that enables Geron to manufacture the cardiomyocytes for use in ongoing large animal studies and, ultimately, testing in humans.

Heart Repair By Cardiomyocytes Produced From Human Embryonic Stem Cells

0 comments :

Post a Comment

 
Top
Google Analytics Alternative